Kinyip Gabriel Leung Net Worth

The estimated Net Worth of Gabriel Leung is at least $1.76 Milion dollars as of 4 June 2024. Mr. Leung owns over 964 units of NovoCure Ltd stock worth over $1,346,955 and over the last 14 years he sold NVCR stock worth over $23,030. In addition, he makes $389,970 as Independent Director at NovoCure Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Leung NVCR stock SEC Form 4 insiders trading

Kinyip has made over 35 trades of the NovoCure Ltd stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 964 units of NVCR stock worth $23,030 on 4 June 2024.

The largest trade he's ever made was exercising 140,000 units of NovoCure Ltd stock on 15 May 2018 worth over $481,600. On average, Kinyip trades about 9,152 units every 87 days since 2011. As of 4 June 2024 he still owns at least 78,175 units of NovoCure Ltd stock.

You can see the complete history of Mr. Leung stock trades at the bottom of the page.

Kinyip Gabriel Leung biography

Kinyip Leung serves as Independent Director of the Company. Mr. Leung was the Vice Chairman of our Board and an employee of Novocure from 2011 to 2016, coordinating Novocure’s global commercial operations. From 2003 to 2010, he worked for OSI Pharmaceuticals, Inc. (“OSI”), a specialty pharmaceutical company, prior to its acquisition by Astellas Pharma Inc., last serving as executive vice president of OSI and the President of OSI’s Oncology and Diabetes Business. Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as group vice president of the global prescription business at Pharmacia Corporation, a global pharmaceutical and healthcare company. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company. He has been Former director of Pernix Therapeutics Holdings, Inc. from 2016 to 2019; director of Albany Molecular Research Inc. from 2010 to 2016 and of Delcath Systems, Inc. from 2011 to 2014. He holds B.S. with High Honors, University of Texas at Austin; M.S. in Pharmacy (with a concentration in pharmaceutical marketing), University of Wisconsin-Madison.

What is the salary of Kinyip Leung?

As the Independent Director of NovoCure Ltd, the total compensation of Kinyip Leung at NovoCure Ltd is $389,970. There are 16 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.

How old is Kinyip Leung?

Kinyip Leung is 58, he's been the Independent Director of NovoCure Ltd since 2020. There are 13 older and 10 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.

What's Kinyip Leung's mailing address?

Gabriel's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.

Insiders trading at NovoCure Ltd

Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... a Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.

What does NovoCure Ltd do?

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Complete history of Mr. Leung stock trades at NovoCure Ltd

NovoCure Ltd executives and stock owners

NovoCure Ltd executives and other stock owners filed with the SEC include:

• William Doyle,
  Executive Chairman of the Board
• Asaf Danziger,
  President, Chief Executive Officer, Director
• Michael Ambrogi,
  Vice President - Senior Technology Fellow
• Wilhelmus Groenhuysen,
  Chief Operating Officer
• Pritesh Shah,
  Chief Commercial Officer
• Asaf Danziger,
  Pres, CEO & Director
• William F. Doyle,
  Exec. Chairman
• Wilhelmus C. M. Groenhuysen,
  Chief Operating Officer
• Todd C. Longsworth,
  Gen. Counsel
• Ashley Cordova,
  CFO & VP of Investor Relations
• Pritesh Shah,
  Chief Commercial Officer
• William Vernon,
  Lead Independent Director
• Jeryl Hilleman,
  Independent Director
• Martin Madden,
  Independent Director
• Sherilyn McCoy,
  Independent Director
• David Hung,
  Independent Director
• Kinyip Gabriel Leung,
  Independent Director
• Frank Leonard,
  Chief Development Officer
• Todd Longsworth,
  General Counsel
• Ely Benaim,
  Chief Medical Officer
• Ashley Cordova,
  Chief Financial Officer
• Dr. Ely Benaim M.D.,
  Chief Medical Officer
• Barak Ben Arye,
  Gen. Counsel
• Ingrid Goldberg,
  VP of Investor Relations
• Prof. Yoram Palti M.D., Ph.D.,
  Founder & CTO
• Uri Weinberg M.D., Ph.D.,
  Chief Science Officer
• Dr. Ely Benaim,
  Chief Medical Officer
• William Patrick Burke,
  Chief HR Officer
• Prof. Yoram Palti,
  Founder & CTO
• Timothy J Scannell,
  
• Eilon D. Kirson,
  Chief Scientific Officer
• Gert L.Volati Ltd Perlhagen,
  
• Peter M. Melnyk,
  Chief Commercial Officer
• Yoram Palti,
  Chief Technology Officer
• Charles G Iii Phillips,
  Director
• Louis J Jr Lavigne,
  Director
• Ltd Volati,
  10% owner
• William Fwfd Ventures Fund ...,
  
• Gert L. Perlhagen,
  Director
• William T. Burkoth,
  Director
• Capital Vii, L.P.Pomona Cap...,
  
• Moshe Giladi,
  Chief Science Officer
• Nicolas Leupin,
  Chief Medical Officer
• Robert J Jr Mylod,
  Director
• Timothy J. Langloss,
  Director
• Hansjoerg Wyss,
  10% owner
• Allyson J Ocean,
  
• William Patrick Burke,
  Chief Human Resources Officer
• Uri Weinberg,
  Chief Innovation Officer
• W Anthony Vernon,
  
• Kristin Stafford,
  
• Gabriel Leung,
  
• Arye Barak Ben,
  General Counsel
• Michal Nath Puri,
  Chief Human Resources Officer